Novo’s Value Surpasses Denmark GDP After Obesity Drug Boost
- Novo is worth the same as all other Danish blue chips combined
- Shares have risen on the back of weight-loss drug Wegovy
This article is for subscribers only.
Novo Nordisk A/S has just reached another milestone in its meteoric rise: the market value of the Danish company has exceeded the size of its domestic economy.
The shares surged this week on news weight-loss drug Wegovy comes with a heart benefit. The gain catapulted the market capitalization above 2.87 trillion kroner ($423 billion), more than Denmark’s 2022 gross domestic product, and means Novo is vying for the title of Europe’s most valuable company.